119 related articles for article (PubMed ID: 38192114)
21. Pre-chemoradiotherapy low hemoglobin levels indicate increased osteoradionecrosis risk in locally advanced nasopharyngeal cancer patients.
Yilmaz B; Somay E; Topkan E; Pehlivan B; Selek U
Eur Arch Otorhinolaryngol; 2023 May; 280(5):2575-2584. PubMed ID: 36749372
[TBL] [Abstract][Full Text] [Related]
22. Pan‑immune‑inflammation value as a novel prognostic biomarker in nasopharyngeal carcinoma.
Su Z; Tang J; He Y; Zeng WH; Yu Q; Cao XL; Zou GR
Oncol Lett; 2024 Jun; 27(6):252. PubMed ID: 38646495
[TBL] [Abstract][Full Text] [Related]
23. Can 3D pseudo-continuous arterial spin labeling perfusion imaging be applied to predict early response to chemoradiotherapy in patients with advanced nasopharyngeal carcinoma?
Sun Z; Hu S; Xue Q; Jin L; Huang J; Dou W
Radiother Oncol; 2021 Jul; 160():97-106. PubMed ID: 33951492
[TBL] [Abstract][Full Text] [Related]
24. Baseline Low Prognostic Nutritional Index Predicts Poor Survival in Locally Advanced Nasopharyngeal Carcinomas Treated With Radical Concurrent Chemoradiotherapy.
Topkan E; Yucel Ekici N; Ozdemir Y; Besen AA; Mertsoylu H; Sezer A; Selek U
Ear Nose Throat J; 2021 Feb; 100(2):NP69-NP76. PubMed ID: 31184210
[TBL] [Abstract][Full Text] [Related]
25. Novel pretreatment nomograms based on pan-immune-inflammation value for predicting clinical outcome in patients with head and neck squamous cell carcinoma.
Chen Q; Wang SY; Chen Y; Yang M; Li K; Peng ZY; Xu CW; Yao XB; Li HH; Zhao Q; Cao YD; Bai YX; Li X
Front Oncol; 2024; 14():1399047. PubMed ID: 38915366
[TBL] [Abstract][Full Text] [Related]
26. Comparison of concurrent chemoradiotherapy versus neoadjuvant chemotherapy followed by radiation in patients with advanced nasopharyngeal carcinoma in endemic area: experience of 128 consecutive cases with 5 year follow-up.
Wu SY; Wu YH; Yang MW; Hsueh WT; Hsiao JR; Tsai ST; Chang KY; Chang JS; Yen CJ
BMC Cancer; 2014 Oct; 14():787. PubMed ID: 25351202
[TBL] [Abstract][Full Text] [Related]
27. Progress report of a randomized trial comparing long-term survival and late toxicity of concurrent chemoradiotherapy with adjuvant chemotherapy versus radiotherapy alone in patients with stage III to IVB nasopharyngeal carcinoma from endemic regions of China.
Chen Y; Sun Y; Liang SB; Zong JF; Li WF; Chen M; Chen L; Mao YP; Tang LL; Guo Y; Lin AH; Liu MZ; Ma J
Cancer; 2013 Jun; 119(12):2230-8. PubMed ID: 23576020
[TBL] [Abstract][Full Text] [Related]
28. Chemoradiotherapy with weekly low-dose docetaxel and cisplatin concurrent with radiation for patients with locally advanced nasopharyngeal carcinoma, followed by adjuvant chemotherapy for selected patients.
Nakahara S; Hanamoto A; Seo Y; Miyaguchi S; Yamamoto Y; Tomiyama Y; Yoshii T; Takenaka Y; Yoshioka Y; Isohashi F; Ogawa K; Inohara H
Jpn J Clin Oncol; 2016 Oct; 46(10):903-910. PubMed ID: 27474126
[TBL] [Abstract][Full Text] [Related]
29. Low Advanced Lung Cancer Inflammation Index Predicts Poor Prognosis in Locally Advanced Nasopharyngeal Carcinoma Patients Treated with Definitive Concurrent Chemoradiotherapy.
Topkan E; Ozdemir Y; Kucuk A; Guler OC; Sezer A; Besen AA; Mertsoylu H; Senyurek S; Kilic Durankus N; Bolukbasi Y; Selek U; Pehlivan B
J Oncol; 2020; 2020():3127275. PubMed ID: 33082783
[TBL] [Abstract][Full Text] [Related]
30. Pretreatment serum vitamin level predicts severity of radiation-induced oral mucositis in patients with nasopharyngeal carcinoma.
Chen G; Jiang H; Jiang D; Wu Q; Li Z; Hua X; Hu X; Zhao H; Wang X; Yu H; Xie C; Zhong Y
Head Neck; 2021 Apr; 43(4):1153-1160. PubMed ID: 33300654
[TBL] [Abstract][Full Text] [Related]
31. Meta-Analysis on Induction Chemotherapy in Locally Advanced Nasopharyngeal Carcinoma.
Mané M; Benkhaled S; Dragan T; Paesmans M; Beauvois S; Lalami Y; Szturz P; Gaye PM; Vermorken JB; Van Gestel D
Oncologist; 2021 Jan; 26(1):e130-e141. PubMed ID: 32924198
[TBL] [Abstract][Full Text] [Related]
32. Administration of oral maintenance chemotherapy for 1 year following definitive chemoradiotherapy may improve the survival of patients with stage N3 nasopharyngeal carcinoma.
Zong J; Liu Y; Liang Q; Xu H; Chen B; Guo Q; Xu Y; Hu C; Pan J; Lin S
Oral Oncol; 2021 Jul; 118():105313. PubMed ID: 33940533
[TBL] [Abstract][Full Text] [Related]
33. Maintenance chemotherapy using S-1 following definitive chemoradiotherapy in patients with N3 nasopharyngeal carcinoma.
Zong J; Xu H; Chen B; Guo Q; Xu Y; Chen C; Weng Y; Zheng W; Pan J; Lin S
Radiat Oncol; 2019 Oct; 14(1):182. PubMed ID: 31640719
[TBL] [Abstract][Full Text] [Related]
34. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy with or without nimotuzumab in the treatment of locally advanced nasopharyngeal carcinoma: a retrospective study.
Yang Z; Zuo Q; Liu R; Wu H; Xiong L; Jia J; Xiang Z
BMC Cancer; 2023 Nov; 23(1):1140. PubMed ID: 37996813
[TBL] [Abstract][Full Text] [Related]
35. Treatment outcomes and late toxicities of 869 patients with nasopharyngeal carcinoma treated with definitive intensity modulated radiation therapy: new insight into the value of total dose of cisplatin and radiation boost.
Ou X; Zhou X; Shi Q; Xing X; Yang Y; Xu T; Shen C; Wang X; He X; Kong L; Ying H; Hu C
Oncotarget; 2015 Nov; 6(35):38381-97. PubMed ID: 26485757
[TBL] [Abstract][Full Text] [Related]
36. Postchemoradiotherapy systemic inflammation response index predicts treatment response and overall survival for patients with locally advanced nasopharyngeal cancer.
Lu YF; Wu CY; Lo WC; Chiu YL; Shueng PW; Hsieh CH; Hsu CX; Kuo DY; Hou PY; Liao LJ
J Formos Med Assoc; 2023 Nov; 122(11):1141-1149. PubMed ID: 37202235
[TBL] [Abstract][Full Text] [Related]
37. Addition of Definitive Radiotherapy to Chemotherapy in Patients With Newly Diagnosed Metastatic Nasopharyngeal Cancer.
Verma V; Allen PK; Simone CB; Gay HA; Lin SH
J Natl Compr Canc Netw; 2017 Nov; 15(11):1383-1391. PubMed ID: 29118230
[No Abstract] [Full Text] [Related]
38. The detrimental effects of radiotherapy interruption on local control after concurrent chemoradiotherapy for advanced T-stage nasopharyngeal carcinoma: an observational, prospective analysis.
Yao JJ; Jin YN; Wang SY; Zhang F; Zhou GQ; Zhang WJ; Zhi-Bin ; Cheng ; Ma J; Qi ZY; Sun Y
BMC Cancer; 2018 Jul; 18(1):740. PubMed ID: 30012115
[TBL] [Abstract][Full Text] [Related]
39. Prognostic significance of the total dose of cisplatin administered during concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma.
Loong HH; Ma BB; Leung SF; Mo F; Hui EP; Kam MK; Chan SL; Yu BK; Chan AT
Radiother Oncol; 2012 Sep; 104(3):300-4. PubMed ID: 22300609
[TBL] [Abstract][Full Text] [Related]
40. The value of integrating tumor volume and plasma Epstein-Barr virus DNA load during sequential chemoradiotherapy for prognostic prediction and therapeutic guidance in high-risk locoregionally advanced nasopharyngeal carcinoma.
Wang G; Dong Z; Huang C; Du X; Chen L; Li K; Guo R; Tang L; Ma J
Oral Oncol; 2023 Oct; 145():106500. PubMed ID: 37467683
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
